Skip to content

The Effect of Esketamine as an Adjuvant to Ropivacaine on Rebound Pain after Nerve Block in Elderly Patients with Upper Limb Fracture: A Single-Center, Double-Blind, Randomized, Controlled Clinical Trial

The Effect of Esketamine as an Adjuvant to Ropivacaine on Rebound Pain after Nerve Block in Elderly Patients with Upper Limb Fracture: A Single-Center, Double-Blind, Randomized, Controlled Clinical Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600118301
Enrollment
Unknown
Registered
2026-02-04
Start date
2026-02-20
Completion date
Unknown
Last updated
2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rebound Pain

Interventions

S group:Nerve block medications: 0.5 mg/kg esketamine + 0.35% ropivacaine, total volume 20 mL
L group:Nerve block medication: 0.35% ropivacaine 20 mL

Sponsors

Wusheng County People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
75 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 75 years, any gender; 2. Patients scheduled for elective upper limb orthopedic surgery; 3. ASA classification I-III; 4. Voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with coagulation disorders or systemic/local infections; 2. Patients with a history of neurological, psychological, or neuromuscular diseases; 3. Patients who require long-term use of analgesics due to chronic pain; 4. Patients undergoing bilateral upper limb surgery; 5. Patients with multiple injuries requiring other surgeries or alternative analgesics; 6. Patients with preoperative nerve damage; 7. Patients allergic to the study drug; 8. Patients with poorly controlled hypertension; 9. Patients with uncontrolled hyperthyroidism; 10. Patients with diabetes complicated by peripheral neuropathy; 11. Patients with poor treatment compliance; 12. Patients with poor language ability who cannot be assessed using the corresponding scales; 13. Patients or their relatives who refuse to sign the informed consent form; 14. Patients who refuse to use PCIA postoperatively; 15. Patients expected to be admitted to the ICU postoperatively.

Design outcomes

Primary

MeasureTime frame
Rebound pain intensity at different time points;anxiety and depression scores;

Secondary

MeasureTime frame
Vital signs data at different time points;Intraoperative consumption of vasoactive drugs; Consumption of anesthetic and analgesic drugs during the intraoperative and patient-controlled analgesia (PCA) periods;MMSE score preoperatively;3D-CAM scores from postoperative day 1 to day 7;Nausea, vomiting and other adverse effects;Length of hospital stay;

Countries

China

Contacts

Public ContactHe Xiang

Wusheng County People's Hospital, Guang'an City, Sichuan Province

624074327@qq.com+86 181 8026 2316

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026